Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Analyst Ratings
Downgrades
News
BTIG Downgrades Magenta Therapeutics to Neutral
BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.
by
Benzinga Newsdesk
January 26, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:
MGTA
) from Buy to Neutral.
Total
0
Shares
Share
0
Tweet
0
Share
0
Share
0
Share
0
Share
0